Clinical Scorecard: Assessment of Hepatic Safety for the Dual Neurokinin-1/-3 Receptor Antagonist Elinzanetant
At a Glance
Category
Detail
Condition
Vasomotor symptoms (VMS) related to menopause or endocrine therapy for breast cancer
Key Mechanisms
Selective dual NK-1 and NK-3 receptor antagonism targeting KNDy neurons in the hypothalamus
Target Population
Postmenopausal women experiencing moderate-to-severe VMS, including those on endocrine therapy for breast cancer
Care Setting
Outpatient management with clinical monitoring during treatment
Key Highlights
Elinzanetant 120 mg shows low risk of liver injury in women with menopausal or endocrine therapy-related VMS.
Independent liver safety board concluded no need for routine liver test monitoring post-approval due to absence of serious liver issues.
Elinzanetant lacks structural features associated with hepatotoxicity and is metabolized primarily via CYP3A4 without formation of reactive intermediates.
Guideline-Based Recommendations
Diagnosis
Diagnosis of VMS based on clinical symptoms in postmenopausal women or women undergoing endocrine therapy for breast cancer.
Management
Use of elinzanetant 120 mg as a nonhormonal treatment option for moderate-to-severe VMS.
No routine liver enzyme monitoring required after approval based on clinical trial safety data.
Monitoring & Follow-up
Liver tests were not deemed necessary post-approval due to similar mild liver test changes in elinzanetant and placebo groups.
Monitoring may be considered in clinical practice based on individual risk factors but is not mandated.
Risks
Low risk of drug-induced liver injury (DILI) with elinzanetant compared to other NK-3 antagonists like fezolinetant.
No evidence of on-target hepatotoxicity due to minimal liver expression of NK-1 and NK-3 receptors.
Patient & Prescribing Data
Postmenopausal women with moderate-to-severe VMS, including those receiving endocrine therapy for breast cancer.
Elinzanetant 120 mg administered up to 26 weeks (and longer in extension studies) demonstrated favorable hepatic safety profile with no serious liver adverse events.
Clinical Best Practices
Consider elinzanetant as a nonhormonal treatment for VMS in appropriate patients.
Reassure patients regarding low hepatic risk based on clinical trial data and independent safety board review.
Remain vigilant for any unexpected liver-related symptoms during treatment despite low risk.
